Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
暂无分享,去创建一个
F. Lordick | M. Ducreux | Y. Hotko | T. Ciuleanu | M. Peeters | T. Price | L. Roman | A. Cervantes | C. Punt | T. André | A. Sobrero | R. Sidhu | Ying Tian | G. Wilson | A. Strickland | E. Cutsem | E. Chan
[1] E. Van Cutsem,et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Vasile,et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. , 2011, Critical reviews in oncology/hematology.
[3] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Stockler,et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Van Cutsem,et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] S. Dakhil,et al. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. , 2010, Clinical colorectal cancer.
[8] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[9] J. Kim,et al. The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients , 2009, Oncology.
[10] E. Van Cutsem,et al. Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy , 2009, Cancer.
[11] W. Scheithauer,et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W. Scheithauer,et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Dongsheng Tu,et al. Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.
[16] Sung Sook Lee,et al. A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer , 2007, Journal of Korean medical science.
[17] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T. Frebourg,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.
[21] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[22] E. Van Cutsem,et al. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] E. Van Cutsem,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[24] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[25] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[26] R. Greil,et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer , 2011, Journal of Cancer Research and Clinical Oncology.
[27] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.